ライフサイエンスコーパス: patent foramen ovale

1 coronary arteries and migraine patients with patent foramen ovale.

2 term outcomes after transcatheter closure of patent foramen ovale.

3 patients who completed echocardiography had patent foramen ovale.

4 DVT and paradoxical embolism due to existing patent foramen ovale.

5 , to medical therapy alone or closure of the patent foramen ovale.

6 c medications or percutaneous closure of the patent foramen ovale.

7 or transient ischemic attack (TIA) and had a patent foramen ovale.

8 ld, limited to pulmonary artery stenosis and patent foramen ovale.

9 es with isolated atrial septal defect and/or patent foramen ovale.

10 and contrast transcranial doppler to detect patent foramen ovale.

11 t (1.07, 0.95 to 1.21), atrial septal defect/patent foramen ovale (1.04, 0.88 to 1.24), neural tube d

12 Of 11 patients, 5 (45%) had a patent foramen ovale; 1 of these also had a primary lung

13 rsus 36.5% in patient with ECs; P<0.001) and patent foramen ovale (4.6% versus 13.5%; P=0.002).

14 in selected symptomatic patients, closure of patent foramen ovale after cryptogenic stroke, treatment

15 Patent foramen ovale, alone or together with ASA, was no

16 The prevalence of patent foramen ovale among patients with cryptogenic str

17 The association of patent foramen ovale and atrial septal aneurysm with str

18 Patients with a patent foramen ovale and ischemic stroke, transient isch

19 and development of anatomic variants such as patent foramen ovale and left atrial septal pouch.

20 Patent foramen ovale and pulmonary arteriovenous shunts

21 ardiography identified three patients with a patent foramen ovale and right-to-left shunt flow while

22 occurred in 47% (including 17% with isolated patent foramen ovale), and 11% had undetermined stroke e

23 res, 15 patients had simultaneous closure of patent foramen ovale, and 19 patients had other various

24 Baseline prevalence of atrial fibrillation, patent foramen ovale, and arterial stenoses were also si

25 inesis, persistent pulmonary hypertension, a patent foramen ovale, and free-floating right-heart thro

26 eart disease, presence of left common trunk, patent foramen ovale, and time for atrial fibrillation d

27 uding occult paroxysmal atrial fibrillation, patent foramen ovale, aortic arch atherosclerosis, atria

28 ion of cryptogenic embolism in patients with patent foramen ovale are administration of antithromboti

29 Structural heart disease and a patent foramen ovale are strongly associated with the pr

30 r device closure (9 secundum ASDs and 4 with patent foramen ovale associated with a cerebral vascular

31 valves has been reported in patients with a patent foramen ovale, carcinoid tumor of the lung, and a

32 Initial results using these tools to perform patent foramen ovale closure are described.

33 acement in 4 and repair in 2, CABG in 2, and patent foramen ovale closure in 5.

34 Evidence from trials suggests that patent foramen ovale closure is superior to medical ther

35 th no apparent increased risk for concurrent patent foramen ovale closure or mitral or tricuspid repa

36 FLOAT (Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Fibrillation

37 rolling patients who underwent transcatheter patent foramen ovale closure to prevent recurrent cerebr

38 roup analysis demonstrated that simultaneous patent foramen ovale closure was not associated with an

39 data on the impact of sex on outcomes after patent foramen ovale closure, however, remains scarce.

40 tation, left atrial appendage occlusion, and patent foramen ovale closure, profoundly differ with res

41 Septal Occluder, are used for transcatheter patent foramen ovale closure.

42 her risk of developing device syndrome after patent foramen ovale closure.

43 ents with nickel hypersensitivity undergoing patent foramen ovale closure.

44 anticoagulation for atrial fibrillation, and patent foramen ovale closure.

45 nts with cryptogenic stroke or TIA who had a patent foramen ovale, closure with a device did not offe

46 As a demonstration of both technologies, patent foramen ovale creation and closure was performed

47 reflect mainly the adult population, such as patent foramen ovale device closure and closure of posti

48 Closure of a patent foramen ovale for secondary prevention of cryptog

49 One possible exception is patent foramen ovale, for which high-risk features may w

50 Patent foramen ovale has been associated with increased

51 %), followed by ostium secundum ASD in 6 and patent foramen ovale in 4.

52 ificant benefit associated with closure of a patent foramen ovale in adults who had had a cryptogenic

53 ment with warfarin or aspirin as part of the Patent Foramen Ovale in Cryptogenic Stroke Study (PICSS)

54 The Patent foramen ovale In Cryptogenic Stroke Study (PICSS)

55 e trials (the PRIMA [Percutaneous Closure of Patent Foramen Ovale in Migraine With Aura] and PREMIUM

56 geal echocardiograms in 11 patients showed a patent foramen ovale in one patient but no systemic sour

57 When pulmonary embolism coexists with a patent foramen ovale, increased pressure in the right at

58 Whether closure of a patent foramen ovale is effective in the prevention of r

59 Patent foramen ovale is present in approximately 25% of

60 the use of percutaneous closure devices for patent foramen ovale is reviewed.

61 presumed paradoxical emboli in patients with patent foramen ovale is unknown.

62 Transcatheter closure of patent foramen ovale may prevent a substantial proportio

63 secundum-type atrial septal defect (n=12) or patent foramen ovale (n=5) by a totally endoscopic appro

64 septal defect, secundum atrial septal defect/patent foramen ovale, neural tube defect, clubfoot, and

65 rocedure (11%), aortic valve procedure (9%), patent foramen ovale or atrial septal defect closure (23

66 r closure of secundum atrial septal defects, patent foramen ovale, patent ductus arteriosus, stent pl

67 ned patients 18 to 60 years of age who had a patent foramen ovale (PFO) and had had a cryptogenic isc

68 A causal relationship between patent foramen ovale (PFO) and migraine has been hypothe

69 dary prevention of embolism in patients with patent foramen ovale (PFO) and otherwise unexplained isc

70 nsient ischemic attack presumably related to patent foramen ovale (PFO) are at risk for recurrent cer

71 The role of a patent foramen ovale (PFO) as a risk factor for ischemic

72 Patent foramen ovale (PFO) can be detected in up to 43%

73 The main randomized trials evaluating patent foramen ovale (PFO) closure after a presumed PFO-

74 al incidence of atrial arrhythmia (AA) after patent foramen ovale (PFO) closure and whether this comp

75 re well-documented, those for catheter-based patent foramen ovale (PFO) closure are still evolving.

76 date of patients who underwent transcatheter patent foramen ovale (PFO) closure for paradoxical embol

77 al, medical devices may be used "off-label." Patent foramen ovale (PFO) closure is indicated to reduc

78 Percutaneous transcatheter patent foramen ovale (PFO) closure is now standard pract

79 Patent foramen ovale (PFO) closure is the gold standard

80 Transcatheter patent foramen ovale (PFO) closure is the recommended tr

81 bservational studies have shown percutaneous patent foramen ovale (PFO) closure to be a safe means of

82 Trials of patent foramen ovale (PFO) closure to prevent recurrent

83 t is observed in up to 25% of patients after patent foramen ovale (PFO) closure, but its long-term in

84 TCA), left atrial appendage (LAA) occlusion, patent foramen ovale (PFO) closure, transcatheter aortic

85 Patent foramen ovale (PFO) describes a valve in the inte

86 The role of surgical closure of patent foramen ovale (PFO) for cerebral infarction (CI)

87 nts to close atrial septal defects (ASD) and patent foramen ovale (PFO) has a number of limitations,

88 Patent foramen ovale (PFO) has been associated with migr

89 Adults with a patent foramen ovale (PFO) have a greater tendency to de

90 to assess the risk of ischemic stroke from a patent foramen ovale (PFO) in the multiethnic prospectiv

91 The efficacy of closure of a patent foramen ovale (PFO) in the prevention of recurren

92 The patent foramen ovale (PFO) is a normal interatrial commu

93 Patent foramen ovale (PFO) is associated with cryptogeni

94 Patent foramen ovale (PFO) is associated with stroke, bu

95 Patent foramen ovale (PFO) is experiencing increased cli

96 Patent foramen ovale (PFO) is implicated in platypnea-or

97 Patent foramen ovale (PFO) is implicated in the pathogen

98 nous anastomoses (IPAVA) in humans without a patent foramen ovale (PFO) is negatively correlated with

99 Patent foramen ovale (PFO) is prevalent in patients with

100 Percutaneous transcatheter closure of patent foramen ovale (PFO) is used as an alternative to

101 A patent foramen ovale (PFO) may permit arterial embolizat

102 ive effectiveness of percutaneous closure of patent foramen ovale (PFO) plus medical therapy versus m

103 Patent foramen ovale (PFO) prevalence was 47% in Tibetan

104 pothesized that paradoxical embolism through patent foramen ovale (PFO) should be the main mechanism.

105 ke risk factors, regular dentist visits, and patent foramen ovale (PFO) status.

106 Patent foramen ovale (PFO) was detected with contrast in

107 o right-to-left shunted blood flow through a patent foramen ovale (PFO) would not be cooled.

108 A patent foramen ovale (PFO), an opening between the right

109 atients with atrial septal aneurysm (SA) and patent foramen ovale (PFO), and to determine the efficac

110 sought to determine the association between patent foramen ovale (PFO), atrial septal aneurysm (ASA)

111 igraine headache symptoms in patients with a patent foramen ovale (PFO), both of which conditions are

112 A milder form of atrial septal defect, patent foramen ovale (PFO), exists in about one-quarter

113 udy was to evaluate the relationship between patent foramen ovale (PFO), ischemic stroke, and subclin

114 Controversy surrounds the issue of patent foramen ovale (PFO), stroke, and secondary preven

115 recurrent ischemic stroke, and prevalence of patent foramen ovale (PFO).

116 procedures to repair incidentally discovered patent foramen ovale (PFO).

117 se, resulting in a right-to-left shunt via a patent foramen ovale (PFO).

118 bolism including ischaemic stroke [through a patent foramen ovale (PFO)].

119 ed its utility in quantitative assessment of patent foramen ovales (PFO).

120 Patent foramen ovales (PFOs) are common congenital cardi

121 Whether closure of a patent foramen ovale reduces the risk of recurrence of i

122 rolling patients with cryptogenic stroke and patent foramen ovale-related ischemic stroke to receive

123 l heart diseases causing stroke, the role of patent foramen ovale remains controversial.

124 vere decompression sickness with concomitant patent foramen ovale that was successfully closed contra

125 theter closure of an atrial septal defect or patent foramen ovale to assess how the procedure affecte

126 Patent foramen ovales vary in both anatomical and functi

127 In the second group, the patent foramen ovale was not successfully created in 1 a

128 tudies of medical therapy (895 patients) for patent foramen ovale were included.

129 transcatheter closure or medical therapy for patent foramen ovale were required to include at least 1

130 All patent foramen ovales were completely closed in the firs

131 randomly assigned to undergo closure of the patent foramen ovale with the Amplatzer PFO Occluder or